Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Plasma cell myeloma
ADR ID BADD_A03440
ADR Hierarchy
01      Blood and lymphatic system disorders
01.14      Plasma cell neoplasms
01.14.02      Plasma cell myelomas
01.14.02.004      Plasma cell myeloma
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.23      Plasma cell neoplasms
16.23.02      Plasma cell myelomas
16.23.02.004      Plasma cell myeloma
Description A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. [MeSH]
MedDRA Code 10035226
MeSH ID D009101; D009101; D009101; D000075122; D009101
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
IGA myeloma | IGD myeloma | IGE myeloma | IGG myeloma | Multiple myeloma | Multiple myeloma and immunoproliferative neoplasms | Multiple myeloma myelomatosis | Multiple myeloma without mention of remission | Myeloma | Myeloma, malignant | Myelomatosis | Myelomatosis multiple | Nonsecretory myeloma | Plasma cell myeloma | Multiple myeloma progression | Multiple myeloma transformation | Smoldering myeloma | Multiple Myeloma | Multiple Myelomas | Myelomas, Multiple | Myeloma, Multiple | Myeloma, Plasma-Cell | Myeloma, Plasma Cell | Myelomas, Plasma-Cell | Plasma-Cell Myeloma | Plasma-Cell Myelomas | Myelomatoses | Plasma Cell Myeloma | Cell Myeloma, Plasma | Cell Myelomas, Plasma | Myelomas, Plasma Cell | Plasma Cell Myelomas | Kahler Disease | Disease, Kahler | Myeloma-Multiple | Myeloma Multiple | Myeloma-Multiples
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
C-Jun-amino-terminal kinase-interacting protein 1Q9UQF2T59459
Dual specificity mitogen-activated protein kinase kinase 7Q8CE90Not Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01223Ixazomib0.006324%
BADD_D01250Lasofoxifene--
BADD_D01251Latanoprost--
BADD_D01253Lenalidomide0.630597%
BADD_D01300Lisinopril--
BADD_D01322Losartan--
BADD_D01376Melphalan0.000139%
BADD_D01418Methotrexate--
BADD_D01506Muromonab-cd3--
BADD_D01567Nilotinib--
BADD_D01629Osimertinib--
BADD_D01645Oxycodone--
BADD_D01662Pamidronic acid--
BADD_D01668Pantoprazole--
BADD_D01676Paricalcitol--
BADD_D01777Pioglitazone--
BADD_D01783Pirfenidone--
BADD_D01798Pomalidomide0.264020%
BADD_D01817Pramipexole--
BADD_D01818Pramipexole dihydrochloride--
BADD_D01834Prednisone--
BADD_D01835Pregabalin--
BADD_D01858Propagermanium--
BADD_D01903Raloxifene0.000264%
BADD_D01908Ramelteon0.004537%
BADD_D01948Riociguat--
BADD_D01954Rivaroxaban--
BADD_D01978Ruxolitinib--
BADD_D02007Semaxanib--
BADD_D02053Sofosbuvir--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages